Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
1,760.20
+31.30 (1.81%)
At close: Jan 6, 2026
NSE:SUNPHARMA Revenue
Sun Pharmaceutical Industries had revenue of 144.78B INR in the quarter ending September 30, 2025, with 8.93% growth. This brings the company's revenue in the last twelve months to 549.64B, up 9.26% year-over-year. In the fiscal year ending March 31, 2025, Sun Pharmaceutical Industries had annual revenue of 525.78B with 8.42% growth.
Revenue (ttm)
549.64B
Revenue Growth
+9.26%
P/S Ratio
7.68
Revenue / Employee
12.78M
Employees
43,000
Market Cap
4.22T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 525.78B | 40.82B | 8.42% |
| Mar 31, 2024 | 484.97B | 46.11B | 10.51% |
| Mar 31, 2023 | 438.86B | 52.31B | 13.53% |
| Mar 31, 2022 | 386.54B | 51.56B | 15.39% |
| Mar 31, 2021 | 334.98B | 6.61B | 2.01% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Sun Pharmaceutical Industries News
- 3 days ago - Pharma generics: Semaglutide patent expiry to open Rs 50bn opportunity; Indian players eye FY27 boost - The Times of India
- 6 days ago - Dr Reddy, Cipla, Sun Pharma and other stocks in focus today as Govt bans high-dose Nimesulide formulations - Business Upturn
- 11 days ago - Sun Pharma may face low double-digit EPS hit in worst case, says Kotak - Business Upturn
- 19 days ago - Nifty 50 top losers today, December 18: Sun Pharma, Tata Steel, Power Grid, Asian Paints, Tata Consumer Products and more - Business Upturn
- 19 days ago - Sun Pharma shares fall over 2% after US FDA issues OAI status for Baska facility - Business Upturn
- 19 days ago - Sun Pharma receives US FDA OAI status for Baska facility after Inspection - Business Upturn
- 25 days ago - Nifty 50 top losers today, December 12: Hindustan Unilever, Max Healthcare Institute, Sun Pharma, ITC, Asian Paints and more - Business Upturn
- 27 days ago - Nifty 50 top gainers today, December 10: Eicher Motors, Hindalco Industries, HDFC Life, Tata Steel, Sun Pharma and more - Business Upturn